The board of directors of Venus Medtech (Hangzhou) Inc. entered into a strategic cooperation framework agreement with United Family Healthcare, in exploring new medical service cooperation models to establish the valvular heart disease related diagnosis and treatment cooperation pilot and specialist center by giving full play to their respective capabilities and advantages. According to the Agreement, the Company will cooperate with UFH to establish a diagnosis and treatment cooperation pilot for aortic valve replacement, Venus A-Valve and Venus A-Plus, and both parties will work jointly on the establishment of the valvular heart disease specialist center in the field of disease diagnosis and treatment and postoperative rehabilitation management, so as to better provide patients with the best diagnosis and treatment scheme worldwide. A joint steering committee will be established by both parties to determine the daily operation of the specialist center. The Company, as a globally focused Chinese medical device company engaged in the research & development, manufacture, and commercialization for medical devices related to heart valve diseases, aims to develop innovative products with high clinical value and continuously promote the popularization of innovative therapies in clinic. The Board believes that by leveraging the respective advantages of the parties involved, such cooperation could popularize and optimize the interventional treatment service for heart valve disease, promote the end-use of related products, which can be used as commercial health insurance exploration, having a significantly strategic effect on the long-term development of the Company.